Armata Pharmaceuticals (ARMP) Net Income towards Common Stockholders: 2013-2018
Historic Net Income towards Common Stockholders for Armata Pharmaceuticals (ARMP) over the last 6 years, with Dec 2018 value amounting to -$8.9 million.
- Armata Pharmaceuticals' Net Income towards Common Stockholders fell 282.49% to -$8.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$16.0 million, marking a year-over-year decrease of 11.16%. This contributed to the annual value of -$53.2 million for FY2024, which is 22.71% down from last year.
- Armata Pharmaceuticals' Net Income towards Common Stockholders amounted to -$8.9 million in Q4 2018, which was down 447.76% from -$1.6 million recorded in Q3 2018.
- In the past 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $14.5 million in Q3 2014 and a low of -$14.8 million during Q1 2015.
- Its 3-year average for Net Income towards Common Stockholders is -$4.8 million, with a median of -$3.6 million in 2016.
- Examining YoY changes over the last 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders showed a top increase of 163.67% in 2014 and a maximum decrease of 606.44% in 2014.
- Over the past 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$994,000 in 2014, then crashed by 219.92% to -$3.2 million in 2015, then crashed by 198.74% to -$9.5 million in 2016, then skyrocketed by 75.47% to -$2.3 million in 2017, then plummeted by 282.49% to -$8.9 million in 2018.
- Its Net Income towards Common Stockholders was -$8.9 million in Q4 2018, compared to -$1.6 million in Q3 2018 and -$3.1 million in Q2 2018.